three leading drug companies reported robust third-quarter_earnings , bolstered_by strong_sales of newer , big-selling prescriptions drugs that provide hefty profit_margins . merck &_co. reported a 25_% increase in earnings ; warner-lambert co. 's profit_rose 22_% and eli_lilly &_co. 's net_income rose 24_% . the results_were in line with analysts_' expectations . merck &_co . merck , rahway , n.j. , continued to lead the industry with a strong_sales performance in the human and animal health-products segment . a stronger u.s. dollar reduced third-quarter and first-nine-month sales_growth 2_% and 3_% , respectively . international sales accounted_for 47_% of total company sales for the nine_months , compared_with 50_% a year_earlier . sales for the quarter rose to $ 1.63 billion from $ 1.47 billion . mevacor , merck 's new cholesterol-lowering drug , had higher sales than any other prescription medicine has ever achieved in the u.s. in the year following introduction , the company said_0 . the drug was introduced in west_germany this_year . intense_competition , however , led to unit sales declines for a group of merck 's established human and animal-health products , including aldomet and indocin . in new_york stock_exchange composite_trading yesterday , merck shares_closed at $ 75.25 , up 50_cents . warner-lambert co . warner-lambert , morris plains , n.j. , reported sales that were a record for any quarter and the eighth quarter in a row of 20_% or more per-share_earnings growth . spurred_by growth in world-wide_sales of the company 's prescription_drugs , warner-lambert said_0 1989 will_be the best year in its history , with per-share_earnings expected to increase more_than 20_% to about $ 6.10 . sales for the quarter rose to $_1.11 billion from $_1.03 billion . prescription-drug world-wide_sales rose 9_% in the quarter to $ 340 million ; u.s. sales_rose 15_% . the segment 's growth was led_by sales of the cardiovascular drugs lopid , a lipid regulator , and dilzem , a calcium channel blocker . world-wide_sales of warner-lambert 's non-prescription health-care_products , such_as halls cough tablets , rolaids antacid , and lubriderm skin lotion , increased 3_% to $ 362 million in the third_quarter ; u.s. sales_rose 5_% . confectionery products sales also had strong_growth in the quarter . world-wide_sales of trident gum , certs breath mints , and clorets gum and breath mints , increased 12_% to $ 277 million . warner-lambert shares_closed at $ 109.50 a_share , up $_1.50 , in big_board composite_trading yesterday . eli_lilly &_co . lilly attributed record third-quarter and nine-month results to world-wide gains for pharmaceuticals , medical instruments and plant-science products despite poor exchange_rates for the dollar that slowed sales abroad . earnings continued to pace sales because of a lower tax_rate , profit from the renegotiation of the debt instrument received from faberge inc. in_connection with lilly 's sale of elizabeth arden inc. in 1987 , and net proceeds_from the settlement of patent litigation at lilly 's hybritech inc. unit . third-quarter sales of the indianapolis , ind. , company rose_11 % to $ 1.045 billion from $ 940.6 million . nine-month sales grew 12_% to $ 3.39 billion from $ 3.03 billion a year_earlier . sales of prozac , an anti-depressant , led drug-sales increases . higher sales of pesticides and other plant-science products more_than offset a slight decline in the sales of animal-health products to fuel the increase in world-wide agricultural product sales , lilly said_0 . advanced cardiovascular systems_inc. and cardiac pacemakers inc. units led growth in the medical-instrument systems division . lilly shares_closed yesterday in composite_trading on the big_board at $ 62.25 , down_12.5 cents .